Aptevo Reports 93% Clinical Benefit Rate With Mipletamig Triplet in Evaluable Frontline Acute Myeloid Keukemia Patients With TP53 Mutations

Benzinga · 3d ago

Remission results nearly double published ven/aza outcomes in patients with historically limited treatment success